European public figures are deeply concerned about the chance that China might want to make a big contribution to their rescue fund
A Chinese policeman on duty in front of the European Union delegation to China in Beijing / AP
It's fascinating to watch European public figures freak out over a possible "bailout" from China. Though the president of the European Central Bank, according to the BBC, "has denied that eurozone countries are going 'cap in hand' to China" to raise money for their rescue fund, clearly this is exactly what others think is going on, and they're far from okay with it.
Nicolas Dupont-Aignant, a current candidate for the French presidency, has called potential Chinese assistance "dirty money," saying China "exploits its people" and is "a Communist dictatorship." Granted, Dupont-Aignant isn't quite mainstream, being the leader of the Gaullist, euroskeptic Debout la République party. But the Socialist candidate for president, Francois Hollande, has also come out against the plan. "Can we imagine that China ... were it to come to the aid of the euro zone, would do so without any compensation?" he's asked. The French Le Monde has reported that he sees the proposal as an "admission of weakness."
Meanwhile, the head of Germany's BDI, or Federation of German Industries, has gone on-record in a German-language interview in Der Spiegel to say that "if we in Europe so organize the stabilization of the euro that we allow political influence from outside, then we make a great mistake." Elsewhere, German newspapers worry about China itself having financial troubles ill reflected in the "official figures."
What's so interesting, of course, is that the U.S. is already highly dependent on Chinese money. It's hard to think of the last time American leaders got publicly worked up over this, even though plenty of experts have expressed concern. The standard balm to American worries is the same one currently on offer in Europe: China needs the American and European markets just as the U.S., and now Europe, need ready cash. There's a limit to how much the Chinese, according to this argument, are likely to mess with us. They're not, for example, going to pull all their money out in one go.
Why are Europeans so much more anxious about relying on China? There are a couple of obvious explanations. The first is that, for Europeans, this will be a new form of reliance on China -- the U.S. dependence has been going on for a while, so it would be odd for Americans to be similarly excited. It's also a more clear-cut decision to debate than when, for example, China started buying up American dollars by the tanker.
But that's not the most satisfying explanation, not least because some American experts think China bailing out Europe is kind of a great idea. Fareed Zakaria is for it, saying this is China's "opportunity to become a 'responsible stakeholder.'" While others, as The Atlantic's own Max Fisher has pointed out, are a bit jittery at what looks like an emerging Chinese lending policy consciously geared towards political influence, the overall response trend appears, as Fisher's own considered argument demonstrates, to be one of practical acceptance.
So is the difference a result of something else? Xenophobia, perhaps? A more conscious West-versus-rest attitude, given that Europeans don't have the same sense as we do of American exceptionalism? Or does Europe just have more vibrant public debate about policy issues? Your choice of explanation may well rest on your attitude towards free market issues and China itself. One thing's for sure: there's nothing like this kind of outcry from Europe to highlight what's not being talked about in the States. Sure, there are occasional op-eds or candidate sound bites that broach the issue. But when you see how potential new debtors in Europe approach it, that looks like breezy indifference.
Rod Dreher makes a powerful argument for communal religious life in his book, The Benedict Option. But he has not wrestled with how to live side by side with people unlike him.
Donald Trump was elected president with the help of 81 percent of white evangelical voters. Mike Pence, the champion of Indiana’s controversial 2015 religious-freedom law, is his deputy. Neil Gorsuch, a judge deeply sympathetic to religious litigants, will likely be appointed to the Supreme Court. And Republicans hold both chambers of Congress and statehouses across the country. Right now, conservative Christians enjoy more influence on American politics than they have in decades.
And yet, Rod Dreher is terrified.
“Don’t be fooled,” he tells fellow Christians in his new book, The Benedict Option. “The upset presidential victory of Donald Trump has at best given us a bit more time to prepare for the inevitable.”
Long after research contradicts common medical practices, patients continue to demand them and physicians continue to deliver. The result is an epidemic of unnecessary and unhelpful treatments.
First, listen to the story with the happy ending: At 61, the executive was in excellent health. His blood pressure was a bit high, but everything else looked good, and he exercised regularly. Then he had a scare. He went for a brisk post-lunch walk on a cool winter day, and his chest began to hurt. Back inside his office, he sat down, and the pain disappeared as quickly as it had come.
That night, he thought more about it: middle-aged man, high blood pressure, stressful job, chest discomfort. The next day, he went to a local emergency department. Doctors determined that the man had not suffered a heart attack and that the electrical activity of his heart was completely normal. All signs suggested that the executive had stable angina—chest pain that occurs when the heart muscle is getting less blood-borne oxygen than it needs, often because an artery is partially blocked.
Plagues, revolutions, massive wars, collapsed states—these are what reliably reduce economic disparities.
Calls to make America great again hark back to a time when income inequality receded even as the economy boomed and the middle class expanded. Yet it is all too easy to forget just how deeply this newfound equality was rooted in the cataclysm of the world wars.
The pressures of total war became a uniquely powerful catalyst of equalizing reform, spurring unionization, extensions of voting rights, and the creation of the welfare state. During and after wartime, aggressive government intervention in the private sector and disruptions to capital holdings wiped out upper-class wealth and funneled resources to workers; even in countries that escaped physical devastation and crippling inflation, marginal tax rates surged upward. Concentrated for the most part between 1914 and 1945, this “Great Compression” (as economists call it) of inequality took several more decades to fully run its course across the developed world until the 1970s and 1980s, when it stalled and began to go into reverse.
In his first extended press conference at the White House, the president railed against his critics and unspooled a series of bitter complaints.
Have you ever had a job you loved, but one where you felt like you’d achieved everything you could? So you looked for a new job, went through a fairly grueling application process, if you do say so yourself, got the offer. Then you started the job, and you hated it. Worse, all the tricks you’d learned in your old job seemed to be pretty much useless in the new one. Did you ever have that experience?
The president of the United States can sympathize.
Donald Trump held the first extended press conference of his presidency on Thursday, and it was a stunning, disorienting experience. He mused about nuclear war, escalated his feud with the press, continued to dwell on the vote count in November, asked whether a black reporter was friends with the Congressional Black Caucus, and, almost as an afterthought, announced his selection for secretary of labor.
Neither truck drivers nor bankers would put up with a system like the one that influences medical residents’ schedules.
The path to becoming a doctor is notoriously difficult. Following pre-med studies and four years of medical school, freshly minted M.D.s must spend anywhere from three to seven years (depending on their chosen specialty) training as “residents” at an established teaching hospital. Medical residencies are institutional apprenticeships—and are therefore structured to serve the dual, often dueling, aims of training the profession’s next generation and minding the hospital’s labor needs.
How to manage this tension between “education and service” is a perennial question of residency training, according to Janis Orlowski, the chief health-care officer of the Association of American Medical Colleges (AAMC). Orlowski says that the amount of menial labor residents are required to perform, known in the profession as “scut work,” has decreased "tremendously" since she was a resident in the 1980s. But she acknowledges that even "institutions that are committed to education … constantly struggle with this,” trying to stay on the right side of the boundary between training and taking advantage of residents.
The Italian philosopher Julius Evola is an unlikely hero for defenders of the “Judeo-Christian West.”
In the summer of 2014, years before he became the White House chief strategist, Steve Bannon gave a lecture via Skype at a conference held inside the Vatican. He spoke about the need to defend the values of the “Judeo-Christian West”—a term he used 11 times—against crony capitalism and libertarian capitalism, secularization, and Islam. He also mentioned the late Julius Evola, a far-right Italian philosopher popular with the American alt-right movement. What he did not mention is that Evola hated not only Jews, but Christianity, too.
References to Evola abounded on websites such as Breitbart News, The Daily Stormer, and AltRight.com well before The New York Timesnoted the Bannon-Evola connection earlier this month. But few have discussed the fundamental oddity of Evola serving as an intellectual inspiration for the alt-right. Yes, the thinker was a virulent anti-Semite and Nazi sympathizer who influenced far-right movements in Italy from the 1950s until his death in 1974, but shouldn’t his contempt for Christianity make him an unlikely hero for those purporting to defend “Judeo-Christian” values?
By excusing Donald Trump’s behavior, some evangelical leaders enabled the internet provocateur’s ascent.
The Conservative Political Action Conference (CPAC) takes place this week near Washington, D.C., the first such gathering since Donald Trump took office. The conference purports to be a gathering for like-minded folks who believe, generally, in the well-established principles of the conservative movement, as enunciated by the American Conservative Union.
This year, aside from President Trump himself, activist Milo Yiannopoulos was briefly granted a featured speaking slot, and it caused a lot of disruption, garment-rending, gnashing of teeth, and in-fighting on the right.
Yiannopoulos, who prefers to go by MILO (yes, capitalized), is a controversial figure with dubious conservative credentials, most famous for being outrageous during speeches on his college campus tour, soberly called the “Dangerous Faggot” tour. Throughout the 2016 election, Yiannopoulos seemed to enjoy nothing quite so much as the crass, antagonistic side of candidate Trump. He didn’t just celebrate it; he rode it like a wave to greater stardom.
Even when a relatively small number of people participate
The #DeleteUber campaign got another boost this weekend after a former Uber engineer wrote in an essay that she had reported incidents of sexual harassment at the company, and that the company had protected the alleged harasser. Uber CEO Travis Kalanick pledged to immediately look into the incident, hiring former Attorney General Eric Holder to investigate the allegations.
This was not the first round of bad press for Uber in recent weeks. In late January, Uber turned off surge pricing after taxi drivers halted work at JFK airport to protest a President Trump’s executive order on immigration, a move that opponents said helped the company profit from a drivers’ strike. And earlier this month, Kalanick stepped down from a position on President Trump’s economic advisory council after employees and consumers protested his involvement with the administration.
The preconditions are present in the U.S. today. Here’s the playbook Donald Trump could use to set the country down a path toward illiberalism.
It’s 2021, and President Donald Trump will shortly be sworn in for his second term. The 45th president has visibly aged over the past four years. He rests heavily on his daughter Ivanka’s arm during his infrequent public appearances.
Fortunately for him, he did not need to campaign hard for reelection. His has been a popular presidency: Big tax cuts, big spending, and big deficits have worked their familiar expansive magic. Wages have grown strongly in the Trump years, especially for men without a college degree, even if rising inflation is beginning to bite into the gains. The president’s supporters credit his restrictive immigration policies and his TrumpWorks infrastructure program.
Listen to the audio version of this article:Download the Audm app for your iPhone to listen to more titles.
Yet another failed drug trial has prompted soul-searching about the “amyloid hypothesis.”
Last week, the pharmaceutical company Merck pulled the plug on a closely watched Alzheimer’s drug trial. The drug verubecestat, an outside committee concluded, had “virtually no chance” of benefit for patients with the disease.
The failure of one drugis of course disappointing, but verubecestat is only the latest in a string of failed trials all attempting the same strategy to battle Alzheimer’s. That pattern of failure has provoked some rather public soul-searching about the basic hypothesis that has guided Alzheimer’s research for the past quarter century.
The “amyloid hypothesis” began with a simple observation: Alzheimer’s patients have an unusual buildup of the protein amyloid in their brains. Thus, drugs that prevent or remove the amyloid should slow the onset of dementia. Yet all drugs targeting amyloid—including solanezumab from Eli Lilly and bapineuzumab from Pfizer and Johnson & Johnson, to add a few more high-profile flameouts to the fail pile—have not worked so far.